logo
Types of Radiation Therapy

Types of Radiation Therapy

Health Line8 hours ago
There are several different types of radiation therapy. The type that may be recommended for you depends on a variety of factors, such as your cancer, its stage, and your treatment goals.
Radiation therapy is a type of cancer treatment. It uses high doses of radiation to:
kill cancer cells
slow the growth of cancer cells
ease cancer symptoms like bone pain
Researchers estimate that over 30% of people with cancer in the United States receive radiation therapy as a part of their first-line cancer treatment. One-half of people with cancer have radiation therapy at some point in their treatment journey.
This article examines the different types of radiation therapy, how they work, and what they're typically used to treat.
What is external beam radiation therapy?
External beam radiation therapy (EBRT) is the most common type of radiation therapy. It can be used to treat a vast variety of cancers.
In EBRT, a specialized machine is used to aim high-energy particles directly at the cancer.
The machines used to deliver EBRT can resemble a larger version of an X-ray machine or a CT scanner. The most common kind of machine used for EBRT is a linear accelerator.
EBRT is a local treatment, which means it only affects the part of your body affected by cancer. For example, if you're being treated for breast cancer, EBRT will only be focused on the tumor in your breast and not your entire body.
EBRT often involves daily radiation therapy 5 days a week for several weeks. The exact number of weeks you have EBRT can depend on factors like the type of cancer you have, your treatment goals, and the radiation dose used.
You typically have EBRT as an outpatient, meaning that you can return home after your treatment sessions.
Types of particles used for EBRT
Currently, there are several different types of particles used for EBRT, these include:
protons
photons
electrons
Photons
Most EBRT machines use photons, which can reach cancers deep within your body. Photons are the same type of particle used in X-rays. However, the dose of photons received during EBRT is much stronger.
There are several subtypes of photon-based EBRT to be aware of.
Three-dimensional conformal radiation therapy (3D-CRT)
3D-CRT delivers radiation from several different directions and uses imaging like CT scans MRI scans, or PET scans to accurately pinpoint the cancer. A computer program uses the imaging information to develop a treatment plan specific to your tumor.
Intensity-modulated radiation therapy (IMRT)
IMRT is similar to 3D-CRT. However, it uses more numerous, smaller radiation beams. The intensity of these can also be adjusted so that some areas of a tumor get higher doses of radiation than others.
Volumetric modulated arc therapy (VMAT) is a newer way of giving IMRT. In VMAT, the radiation machine moves around you and can adjust the radiation beam during your treatment.
Image-guided radiation therapy (IGRT)
In IGRT, imaging is used to plan treatment, as well as to direct the radiation during a treatment session.
Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
SRS directs a very focused beam containing a high dose of radiation at a tumor and can be used if conventional surgery isn't an option. It's often used for tumors in the brain and other areas inside the skull.
SBRT is essentially the same as SRS, but is given outside of the brain. As such, it may be used for tumors affecting tissues, including but not limited to the lungs, liver, and prostate.
Intraoperative radiation therapy (IORT)
IORT is when you receive radiation during a surgical procedure to treat your cancer. It can be used if a surgeon cannot completely remove a tumor or if the cancer has a high risk of coming back.
Protons
Protons are positively charged particles that can also reach cancers deep in the body. Compared to photons, protons are less likely to scatter within the body, which means healthy tissue is less likely to be exposed to radiation.
Proton-based EBRT can be used to treat cancers affecting the:
eyes
prostate
liver
lung
brain and spinal cord
skull base
head and neck
Electrons
Electrons are negatively charged particles. Compared to photons and protons, they cannot travel that far in the body. Because of this, electrons are typically used for cancers close to the surface of the body, such as those on the skin.
What is internal radiation therapy?
Internal radiation therapy (brachytherapy) is when a radiation source is placed inside your body. This is in contrast to EBRT, where the radiation source is located outside of your body.
However, like EBRT, internal radiation therapy is a type of local treatment, allowing radiation to be inside or near your cancer without affecting other areas of the body.
There are several types of cancer for which internal radiation therapy may be used. Some of the most common include:
It's also possible that internal radiation therapy may be recommended for certain types of:
penile cancer
urethral cancer
head and neck cancer
eye cancer
sarcoma
Radiation sources for internal radiation therapy are implanted during a procedure that uses a catheter or applicator and may involve either general or local anesthesia. Implants can come in a variety of forms, including:
seeds, pellets, or capsules
discs or plaques
tubes or wires
There are three general types of internal radiation therapy.
Low dose internal radiation therapy
A low dose internal radiation therapy implant can typically stay in place from 1 to 7 days, after which it's removed.
High dose internal radiation therapy
In high dose internal radiation therapy, an implant is only left in place for 10 to 20 minutes before being removed. You may have this type of internal radiation therapy twice daily for up to five days or once weekly for up to five weeks.
Permanent internal radiation therapy
A permanent internal radiation therapy implant remains in your body for the rest of your life. The level of radiation from the implant decreases gradually over time.
What is systemic radiation therapy?
In contrast to EBRT and internal radiation therapy, systemic radiation therapy is when the radiation travels throughout your body.
This type of radiation therapy uses drugs to deliver the radiation to the cancer. These can be given by mouth or into your bloodstream via an IV.
There are two types of systemic radiation therapy.
Radioimmunotherapy
Radioimmunotherapy uses radioactive material attached to a monoclonal antibody that's specific to certain types of cancer cells. When the antibody binds to the cancer cell, it delivers the radiation.
This type of systemic radiation therapy can be used for neuroendocrine tumors, prostate cancer, and some kinds of lymphoma.
Peptide receptor radionucleotide therapy (PRRT)
PRRT utilizes radioactive material that's attached to a short protein (peptide). It targets cancer cells with receptors for this peptide. The peptide delivers the radiation when it binds to its receptor on the cancer cell.
PRRT is used for neuroendocrine tumors.
Takeaway
There are several types of radiation therapy. Additionally, each type of radiation therapy has different subtypes.
The type of radiation therapy that's recommended for you can depend on factors like the type of cancer you have, the stage of your cancer, your treatment goals, and your age and overall health.
If radiation therapy is part of your cancer treatment plan, be sure to speak to your doctor about your specific treatment. They can give you more information on things like the procedures involved, how long your treatment will last, and what types of side effects to expect.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

Yahoo

timean hour ago

  • Yahoo

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store